Eyecare company Bausch + Lomb (NYSE: BLCO) will be reporting results this Wednesday before market hours. Here’s what to look for.

Bausch + Lomb met analysts’ revenue expectations last quarter, reporting revenues of $1.28 billion, up 7.1% year on year. It was a satisfactory quarter for the company, with a beat of analysts’ EPS estimates.

Is Bausch + Lomb a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Bausch + Lomb’s revenue to grow 8.2% year on year to $1.38 billion, in line with the 9.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.36 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Bausch + Lomb has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 2.3% on average.

Looking at Bausch + Lomb’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Haemonetics’s revenues decreased 2.7% year on year, beating analysts’ expectations by 2.4%, and Inspire Medical Systems reported revenues up 12.2%, topping estimates by 1.1%. Haemonetics traded down 10% following the results while Inspire Medical Systems was also down 12.5%.

Read our full analysis of Haemonetics’s results here and Inspire Medical Systems’s results here.

Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.7% on average over the last month. Bausch + Lomb’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $17.54 (compared to the current share price of $17.03).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.